Nowadays, mucosal healing is regarded as a major end point in clinical trials and is increasingly used in clinical practice for the management of patients with inflammatory bowel disease. The definition of mucosal healing varies across studies and validated endoscopic scoring indices are still lacking. The advent of anti-tumor necrosis factor agents has changed the way of treating inflammatory bowel disease and high rates of induction and maintenance of mucosal healing can be achieved with this drug class. Mucosal healing is desirable as it may change the natural course of the disease by decreasing surgery and hospitalization rates in both ulcerative colitis and Crohn’s disease.

Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T: Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996;110:45–51.
Peyrin-Biroulet L, Lemann M: Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870–879.
Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang YX, Lang YH, Marano CW, Strauss R, Oddens BJ, Feagan BG, et al: Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–1201.
De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G: Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis 2012;26:22977.
Feagan BG, Lemann M, Befrits R, Connell W, D’Haens G, Ghosh S, Michetti P, Ochsenkuhn T, Panaccione R, Schreiber, et al: Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 2012;18:152–160.
Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF: Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15–29.
Fefferman DS, Farrell RJ: Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 2005;3:11–24.
Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, Present DH, Rutgeerts P, Scholmerich J, Stange EF, et al: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002;122:512–530.
Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, et al: Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 2012;142:1102–1111.
Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao WH, et al: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004;126:402–413.
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P: Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009;15:1295–1301.
D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lemann M, Marteau P, Rutgeerts P, Scholmerich J, et al: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763–786.
Mary JY, Modigliani R: Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983–989.
Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, et al: Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505–512.
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990;99:956–963.
Hebuterne X, Lemann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, D’Haens G, Mitchev K, Ernault E, Vermeire S, et al: Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 2012;23:23.
Efthymiou A, Viazis N, Mantzaris G, Papadimitriou N, Tzourmakliotis D, Raptis S, Karamanolis DG: Does clinical response correlate with mucosal healing in patients with Crohn’s disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis 2008;14:1542–1547.
Gal E, Geller A, Fraser G, Levi Z, Niv Y: Assessment and validation of the new capsule endoscopy Crohn’s disease activity index (CECDAI). Dig Dis Sci 2008;53:1933–1937.
Truelove SC, Witts LJ: Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;2:1041–1048.
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JWD, Dube R, Cohen A, Steinhart AH, Landau, S, et al: Treatment of ulcerative colitis with a humanized antibody to the alpha(4)beta(7) integrin. N Engl J Med 2005;352:2499–2507.
Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative-colitis. A randomized study. N Engl J Med 1987;317:1625–1629.
Travis SPL, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lemann M, Lichtenstein GR, et al: Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535–342.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao WH, et al: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, et al: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–1395.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–2476.
Sandborn WJ, Colombel JF, Reinisch W, Feagan BG, Rachmilewitz D, Olson A, Johanns J, Travers S, Present D, Sands BE, et al: Infliximab induces and maintains mucosal healing in ulcerative colitis patients: the ACT trials. Am J Gastroenterol 2005;100:S310-S.
Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Krane SV, Bruining DH, Cohen RD, et al: Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302–1307.
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257–U150.
Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao WH, Patel K, Wolf DC, Safdi M, Colombel JF, et al: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006;63:433–442.
D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, et al: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660–667.
Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE, et al: Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009;136:441–450.
D’Haens G, Noman M, Baert F, Hiele M, Van Assche G, Daperno M: Endoscopic healing after infliximab treatment for Crohn’s disease provides a longer time to relapse. Gastroenterology 2002;122:A-100.
Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, et al: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138:463–468.
Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D: Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn’s disease. Clin Gastroenterol Hepatol 2010;8:591–599.
Wright R, Truelove SR: Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966;11:847–857.
Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB, et al: Results from the 2nd Scientific Workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. J Crohn Colitis 2011;5:477–483.
Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, et al: Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:483–U117.
Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R: Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97:947–953.
Froslie KF, Jahnsen J, Moum BA, Vatn MH, IBSEN group: Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–422.
Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D’Hoore A, van Steen K, et al: Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn Colitis 2008;2:219–225.
Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451–459.
Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A: Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53:1813–1816.
Rubin DT, Huo D, Rothe JA: Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: a case-control analysis with blinded prospective pathology review. Gastroenterology 2006;130:A2.
Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099–1105.
You do not currently have access to this content.